Donor Cell-derived Leukemia After Cord Blood Transplantation and a Review of the Literature: Differences Between Cord Blood and BM As the Transplant Source

Overview

Journal Bone Marrow Transplant

Specialty General Surgery

Date 2013 Sep 10

PMID 24013690

Citations 19

Authors

H Shiozaki

K Yoshinaga

T Kondo

Y Imai

M Shiseki

N Mori

M Teramura

T Motoji

Affiliations

Soon will be listed here.

Abstract

Donor cell-derived leukemia (DCL) is a rare complication of SCT. Here, we present a case of DCL following cord blood transplantation (CBT) and review the clinical features of previously reported DCL. To our knowledge, this is the first report comparing clinical characteristics of DCL from the standpoint of the transplant source, with umbilical cord blood and BM. AML and myelodysplastic syndrome (MDS) were recognized more frequently in DCL after CBT, whereas the incidence of AML and ALL was similar after BMT. The median duration between the occurrence of DCL following CBT and BMT was 14.5 and 36 months, respectively. DCL occurred in a significantly shorter period after CBT than after BMT. Abnormal karyotypes involving chromosome 7 were observed in 52.4% of CBT recipients and 17.3% of BMT recipients; this was a statistically significant difference. Particularly, the frequency of monosomy 7 was significantly higher in DCL after CBT than after BMT. The types of abnormal karyotypes in DCL following BMT were similar to those characteristically observed in adult de novo AML and MDS. DCL patients generally have a poor prognosis in both groups. SCT is the best treatment for curing DCL. DCL appears to have different clinical features according to the transplant source.

Citing Articles

Editorial: Case reports in hematological malignancies: 2022.

Antar A, Szallasi A, Imataki O Front Oncol. 2023; 13:1272547.

PMID: 37671065 PMC: 10476086. DOI: 10.3389/fonc.2023.1272547.

Venetoclax and Azacitidine in the Treatment of -Mutated Donor Cell-Derived Leukemia in a Patient With Fanconi Anemia: Case Report and Literature Review.

Ma J, Morimoto K, Pulsipher M, Parekh C JCO Precis Oncol. 2023; 7:e2200693.

PMID: 37315262 PMC: 10309544. DOI: 10.1200/PO.22.00693.

Anti-CD19 chimeric antigen receptor T-cell followed by interferon-α therapy induces durable complete remission in donor cell-derived acute lymphoblastic leukemia: A case report.

Ni J, Zhou J, Long Z, Chen X, Chen X, Hong J Front Oncol. 2022; 12:1021786.

PMID: 36505803 PMC: 9731404. DOI: 10.3389/fonc.2022.1021786.

Outcomes of subsequent neoplasms after umbilical cord blood transplantation in Europe.

Rafii H, Ruggeri A, Kenzey C, Sanz J, Peffault De La Tour R, Esquirol A Blood Adv. 2022; 7(10):1976-1986.

PMID: 36350759 PMC: 10189403. DOI: 10.1182/bloodadvances.2022007941.

Lessons Learned from Donor Cell-Derived Myeloid Neoplasms: Report of Three Cases and Review of the Literature.

Deshmukh K, Kelemen K Life (Basel). 2022; 12(4).

PMID: 35455050 PMC: 9028156. DOI: 10.3390/life12040559.

References

Browne P, Lawler M, Humphries P, McCann S . Donor-cell leukemia after bone marrow transplantation for severe aplastic anemia. N Engl J Med. 1991; 325(10):710-3. DOI: 10.1056/NEJM199109053251007. View

Wiseman D, Das M, Poulton K, Liakopoulou E . Donor cell leukemia following unrelated donor bone marrow transplantation for primary granulocytic sarcoma of the small intestine. Am J Hematol. 2011; 86(3):315-8. DOI: 10.1002/ajh.21938. View

Pieroni F, Oliveira F, Panepucci R, Voltarelli J, Simoes B, Falcao R . Development of donor cell derived acute myeloid leukemia after stem cell transplantation for chronic myeloid leukemia. Bone Marrow Transplant. 2006; 37(8):801-2. DOI: 10.1038/sj.bmt.1705332. View

Matsunaga T, Murase K, Yoshida M, Fujimi A, Iyama S, Kuribayashi K . Donor cell derived acute myeloid leukemia after allogeneic cord blood transplantation in a patient with adult T-cell lymphoma. Am J Hematol. 2005; 79(4):294-8. DOI: 10.1002/ajh.20349. View

Rodriguez-Macias G, Martinez-Laperche C, Gayoso J, Noriega V, Serrano D, Balsalobre P . Mutation of the NPM1 gene contributes to the development of donor cell-derived acute myeloid leukemia after unrelated cord blood transplantation for acute lymphoblastic leukemia. Hum Pathol. 2013; 44(8):1696-9. DOI: 10.1016/j.humpath.2013.01.001. View

Nagamura-Inoue T, Kodo H, Takahashi T, Mugishima H, Tojo A, Asano S . Four cases of donor cell-derived AML following unrelated cord blood transplantation for adult patients: experiences of the Tokyo Cord Blood Bank. Cytotherapy. 2007; 9(8):727-8. DOI: 10.1080/14653240701466339. View

Thomas E, Bryant J, Buckner C, Clift R, Fefer A, Johnson F . Leukaemic transformation of engrafted human marrow cells in vivo. Lancet. 1972; 1(7764):1310-3. DOI: 10.1016/s0140-6736(72)91037-9. View

Komeno Y, Kanda Y, Kandabashi K, Kawazu M, Goyama S, Takeshita M . Reduced-intensity bone marrow transplantation from an alternative unrelated donor for myelodysplastic syndrome of first-donor origin. Am J Hematol. 2003; 72(3):220-2. DOI: 10.1002/ajh.10286. View

Fialkow P, Thomas E, Bryant J, Neiman P . Leukaemic transformation of engrafted human marrow cells in vivo. Lancet. 1971; 1(7693):251-5. DOI: 10.1016/s0140-6736(71)90998-6. View

10.

Palka G, Di Bartolomeo P, Iacone A, Di Girolamo G, Betti S, Calabrese G . Cytogenetics and bone marrow transplantation. Cancer Genet Cytogenet. 1986; 21(2):147-57. DOI: 10.1016/0165-4608(86)90040-3. View

11.

Szabolcs P, Cairo M . Unrelated umbilical cord blood transplantation and immune reconstitution. Semin Hematol. 2010; 47(1):22-36. PMC: 3684393. DOI: 10.1053/j.seminhematol.2009.10.009. View

12.

Ando T, Yujiri T, Mitani N, Takeuchi H, Nomiyama J, Suguchi M . Donor cell-derived acute myeloid leukemia after unrelated umbilical cord blood transplantation. Leukemia. 2006; 20(4):744-5. DOI: 10.1038/sj.leu.2404121. View

13.

Kraut L, Trebeljahr G, Thiele B, Fauser A . Donor cell-derived myelodysplastic syndrome in a patient 7 years after unrelated allogeneic HLA-mismatched transplantation for Ph+ chronic myeloid leukemia. Bone Marrow Transplant. 2005; 36(8):737. DOI: 10.1038/sj.bmt.1705125. View

14.

Crow J, Youens K, Michalowski S, Perrine G, Emhart C, Johnson F . Donor cell leukemia in umbilical cord blood transplant patients: a case study and literature review highlighting the importance of molecular engraftment analysis. J Mol Diagn. 2010; 12(4):530-7. PMC: 2893640. DOI: 10.2353/jmoldx.2010.090215. View

15.

Hertenstein B, Hambach L, Bacigalupo A, Schmitz N, McCann S, Slavin S . Development of leukemia in donor cells after allogeneic stem cell transplantation--a survey of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2005; 90(7):969-75. View

16.

Shono Y, Kosugi-Kanaya M, Shiratori S, Sugita J, Fujimoto K, Kondo T . Donor cell leukemia after umbilical cord blood transplantation: recurrent or de novo? The importance of diagnosis for therapeutic decision making. Int J Hematol. 2011; 93(4):563-565. DOI: 10.1007/s12185-011-0814-y. View

17.

Lawler M, Locasciulli A, Longoni D, Schiro R, McCann S . Leukaemic transformation of donor cells in a patient receiving a second allogeneic bone marrow transplant for severe aplastic anaemia. Bone Marrow Transplant. 2002; 29(5):453-6. DOI: 10.1038/sj.bmt.1703372. View

18.

Gopcsa L, Barta A, Banyai A, Konya M, Pajor L, Foldi J . Acute myeloid leukaemia of donor cell origin developing 5 years after allogeneic bone marrow transplantation for chronic myeloid leukaemia. Bone Marrow Transplant. 2002; 29(5):449-52. DOI: 10.1038/sj.bmt.1703378. View

19.

Gustafsson B, Moell J, Leblanc K, Barbany G, Soderhall S, Winiarski J . Donor cell-derived acute myeloid leukemia after second allogenic cord blood transplantation in a patient with Fanconi anemia. Pediatr Transplant. 2011; 16(6):E241-5. DOI: 10.1111/j.1399-3046.2011.01584.x. View

20.

Schmitz N, Johannson W, Schmidt G, von der Helm K, Loffler H . Recurrence of acute lymphoblastic leukemia in donor cells after allogeneic marrow transplantation associated with a deletion of the long arm of chromosome 6. Blood. 1987; 70(4):1099-104. View